Importer of Controlled Substances Application: Mylan Pharmaceuticals, Inc., 16436 [2015-06967]
Download as PDF
<![CDATA[
16436
Federal Register / Vol. 80, No. 59 / Friday, March 27, 2015 / Notices
United States District Judge
XII. No Reacquisition
For a period of five years from the
date of entry of this Final Judgment,
Defendants may not apply for or obtain
any bus stop authorizations for hop-on,
hop-off bus tours at the locations of the
divested CitySights Bus Stop
Authorizations, except that, after May 1,
2016, if the NYCDOT revokes a bus stop
authorization currently granted to an
affiliate of Twin America other than
City Sights, Defendants may apply for or
obtain a bus stop authorization at the
location of a divested CitySights Bus
Stop Authorization that is at or in close
proximity to the location of the bus stop
authorization NYCDOT has revoked.
Nothing in this Final Judgment shall be
construed to prohibit Defendants from
applying for or obtaining from the
NYCDOT bus stop authorizations at
locations other than the locations of the
CitySights Bus Stop Authorizations, nor
to limit the NYCDOT’s ability to alter or
amend Defendants’ bus stop
authorizations.
XIII. Retention of Jurisdiction
This Court retains jurisdiction to
enable any party to this Final Judgment
to apply to this Court at any time for
further orders and directions as may be
necessary or appropriate to carry out or
construe this Final Judgment, to modify
any of its provisions, to enforce
compliance, and to punish violations of
its provisions.
XIV. Expiration of Final Judgment
Unless this Court grants an extension,
this Final Judgment shall expire ten
years from the date of its entry, except
that Sections XI and XII shall expire five
years from the date of this Final
Judgment’s entry.
mstockstill on DSK4VPTVN1PROD with NOTICES
XV. Public Interest Determination
Entry of this Final Judgment is in the
public interest. The parties have
complied with the requirements of the
Antitrust Procedures and Penalties Act,
15 U.S.C. 16, including making copies
available to the public of this Final
Judgment, the Competitive Impact
Statement, and any comments thereon
and the United States’ responses to
comments. Based upon the record
before the Court, which includes the
Competitive Impact Statement and any
comments and response to comments
filed with the Court, entry of this Final
Judgment is in the public interest.
Dated:
lllllllllllllllllllll
lllllllllllllllllllll
Judge Andrew L. Carter, Jr.
VerDate Sep<11>2014
20:59 Mar 26, 2015
Jkt 235001
Controlled substance
Schedule
[FR Doc. 2015–07055 Filed 3–26–15; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Mylan Pharmaceuticals,
Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before April 27, 2015. Such persons
may also file a written request for a
hearing on the application pursuant to
21 CFR 1301.43 on or before April 27,
2015.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on October
13, 2014, Mylan Pharmaceuticals, Inc.,
3711 Collins Ferry Road, Morgantown,
West Virginia 26505, applied to be
registered as an importer of the
following basic classes of controlled
substances:
DATES:
Controlled substance
Amphetamine (1100) ..................
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
Schedule
II
Lisdexamfetamine (1205) ...........
Methylphenidate (1724) ..............
Pentobarbital (2270) ...................
Oxycodone (9143) ......................
Hydromorphone (9150) ..............
Hydrocodone (9193) ...................
Levorphanol (9220) ....................
Morphine (9300) .........................
Oxymorphone (9652) ..................
Remifentanil (9739) ....................
Fentanyl (9801) ..........................
II
II
II
II
II
II
II
II
II
II
II
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
analysis is required to allow the
company to export domesticallymanufactured FDF to foreign markets.
Dated: March 20, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–06967 Filed 3–26–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1140–0031]
Agency Information Collection
Activities: Proposed eCollection
eComments Requested; Records of
Acquisition and Disposition,
Registered Importers of Arms,
Ammunition, and Implements of War
on the U.S. Munitions Imports List
Bureau of Alcohol, Tobacco,
Firearms and Explosives, Department of
Justice.
ACTION: 30-day notice.
AGENCY:
The Department of Justice
(DOJ), Bureau of Alcohol, Tobacco,
Firearms and Explosives (ATF) will
submit the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
This proposed information collection
was previously published in the Federal
Register Volume 80, Number 14, page
3252 on January 22, 2015, allowing for
a 60 day comment period.
DATES: The purpose of this notice is to
allow for an additional 30 days for
public comment until April 27, 2015.
FOR FURTHER INFORMATION CONTACT: If
you have comments, especially on the
estimated public burden or associated
response time, suggestions, or need a
copy of the proposed information
collection instrument with instructions
SUMMARY:
E:\FR\FM\27MRN1.SGM
27MRN1
]]>Agencies
[Federal Register Volume 80, Number 59 (Friday, March 27, 2015)]
[Notices]
[Page 16436]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-06967]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Mylan
Pharmaceuticals, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.34(a) on or before April 27, 2015. Such persons may also file a
written request for a hearing on the application pursuant to 21 CFR
1301.43 on or before April 27, 2015.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODW,
8701 Morrissette Drive, Springfield, Virginia 22152. Request for
hearings should be sent to: Drug Enforcement Administration, Attention:
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Deputy Assistant Administrator of the DEA Office of Diversion
Control (``Deputy Assistant Administrator'') pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on
October 13, 2014, Mylan Pharmaceuticals, Inc., 3711 Collins Ferry Road,
Morgantown, West Virginia 26505, applied to be registered as an
importer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Pentobarbital (2270)....................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Levorphanol (9220)......................... II
Morphine (9300)............................ II
Oxymorphone (9652)......................... II
Remifentanil (9739)........................ II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
finished dosage form (FDF) from foreign sources for analytical testing
and clinical trials in which the foreign FDF will be compared to the
company's own domestically-manufactured FDF. This analysis is required
to allow the company to export domestically-manufactured FDF to foreign
markets.
Dated: March 20, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-06967 Filed 3-26-15; 8:45 am]
BILLING CODE 4410-09-P
